Your browser doesn't support javascript.
loading
Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation.
Ribeiro Guerra, Maximiliano; Coignard, Juliette; Eon-Marchais, Séverine; Dondon, Marie-Gabrielle; Le Gal, Dorothée; Beauvallet, Juana; Mebirouk, Noura; Belotti, Muriel; Caron, Olivier; Gauthier-Villars, Marion; Coupier, Isabelle; Buecher, Bruno; Lortholary, Alain; Fricker, Jean-Pierre; Gesta, Paul; Noguès, Catherine; Faivre, Laurence; Berthet, Pascaline; Luporsi, Elisabeth; Delnatte, Capucine; Bonadona, Valérie; Maugard, Christine M; Pujol, Pascal; Lasset, Christine; Longy, Michel; Bignon, Yves-Jean; Adenis-Lavignasse, Claude; Venat-Bouvet, Laurence; Dreyfus, Hélène; Gladieff, Laurence; Mortemousque, Isabelle; Audebert-Bellanger, Séverine; Soubrier, Florent; Giraud, Sophie; Lejeune-Dumoulin, Sophie; Limacher, Jean-Marc; Chiesa, Jean; Fajac, Anne; Floquet, Anne; Eisinger, François; Tinat, Julie; Fert-Ferrer, Sandra; Colas, Chrystelle; Frebourg, Thierry; Damiola, Francesca; Barjhoux, Laure; Cavaciuti, Eve; Mazoyer, Sylvie; Tardivon, Anne; Lesueur, Fabienne.
Afiliación
  • Ribeiro Guerra M; INSERM, U900, Paris, France.
  • Coignard J; Institut Curie, Paris, France.
  • Eon-Marchais S; Mines ParisTech, Fontainebleau, France.
  • Dondon MG; PSL Research University, Paris, France.
  • Le Gal D; Department of Public Health, Faculty of Medicine, Federal University of Juiz de Fora - UFJF, Minas Gerais, Brazil.
  • Beauvallet J; INSERM, U900, Paris, France.
  • Mebirouk N; Institut Curie, Paris, France.
  • Belotti M; Mines ParisTech, Fontainebleau, France.
  • Caron O; PSL Research University, Paris, France.
  • Gauthier-Villars M; INSERM, U900, Paris, France.
  • Coupier I; Institut Curie, Paris, France.
  • Buecher B; Mines ParisTech, Fontainebleau, France.
  • Lortholary A; PSL Research University, Paris, France.
  • Fricker JP; INSERM, U900, Paris, France.
  • Gesta P; Institut Curie, Paris, France.
  • Noguès C; Mines ParisTech, Fontainebleau, France.
  • Faivre L; PSL Research University, Paris, France.
  • Berthet P; INSERM, U900, Paris, France.
  • Luporsi E; Institut Curie, Paris, France.
  • Delnatte C; Mines ParisTech, Fontainebleau, France.
  • Bonadona V; PSL Research University, Paris, France.
  • Maugard CM; INSERM, U900, Paris, France.
  • Pujol P; Institut Curie, Paris, France.
  • Lasset C; Mines ParisTech, Fontainebleau, France.
  • Longy M; PSL Research University, Paris, France.
  • Bignon YJ; INSERM, U900, Paris, France.
  • Adenis-Lavignasse C; Institut Curie, Paris, France.
  • Venat-Bouvet L; Mines ParisTech, Fontainebleau, France.
  • Dreyfus H; PSL Research University, Paris, France.
  • Gladieff L; Institut Curie, Service de Génétique, Paris, France.
  • Mortemousque I; Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France.
  • Audebert-Bellanger S; Institut Curie, Service de Génétique, Paris, France.
  • Soubrier F; Hôpital Arnaud de Villeneuve, CHU Montpellier, Service de Génétique Médicale et Oncogénétique, Montpellier, France.
  • Giraud S; INSERM 896, CRCM Val d'Aurelle, Montpellier, France.
  • Lejeune-Dumoulin S; Institut Curie, Service de Génétique, Paris, France.
  • Limacher JM; Centre Catherine de Sienne, Service d'Oncologie Médicale, Nantes, France.
  • Chiesa J; Centre Paul Strauss, Unité d'Oncologie, Strasbourg, France.
  • Fajac A; CH Georges Renon, Service d'Oncogénétique Régional Poitou-Charentes, Niort, France.
  • Floquet A; Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli Calmettes, Marseille, France.
  • Eisinger F; Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
  • Tinat J; Institut GIMI, CHU de Dijon, Hôpital d'Enfants, Dijon, France.
  • Fert-Ferrer S; Centre de Lutte contre le Cancer Georges François Leclerc, Dijon, France.
  • Colas C; Centre François Baclesse, Unité de pathologie gynécologique, Caen, France.
  • Frebourg T; Service de Génétique UF4128 CHR Metz-Thionville, Hôpital de Mercy, Metz, France.
  • Damiola F; Centre René Gauducheau, Unité d'Oncogénétique, Nantes, Saint Herblain, France.
  • Barjhoux L; Université Claude Bernard Lyon 1, Villeurbanne, France.
  • Cavaciuti E; CNRS UMR 5558, Lyon, France.
  • Mazoyer S; Centre Léon Bérard, Unité de Prévention et Epidémiologie Génétique, Lyon, France.
  • Tardivon A; Génétique Oncologique moléculaire, UF1422, Département d'Oncobiologie, LBBM, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Lesueur F; UF6948 Génétique Oncologique Clinique, Evaluation familiale et suivi, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Breast Cancer Res ; 23(1): 79, 2021 08 03.
Article en En | MEDLINE | ID: mdl-34344426
ABSTRACT

BACKGROUND:

Diagnostic ionizing radiation is a risk factor for breast cancer (BC). BC risk increases with increased dose to the chest and decreases with increased age at exposure, with possible effect modification related to familial or genetic predisposition. While chest X-rays increase the BC risk of BRCA1/2 mutation carriers compared to non-carriers, little is known for women with a hereditary predisposition to BC but who tested negative for a BRCA1 or BRCA2 (BRCA1/2) mutation.

METHODS:

We evaluated the effect of chest X-rays from diagnostic medical procedures in a dataset composed of 1552 BC cases identified through French family cancer clinics and 1363 unrelated controls. Participants reported their history of X-ray exposures in a detailed questionnaire and were tested for 113 DNA repair genes. Logistic regression and multinomial logistic regression models were used to assess the association with BC.

RESULTS:

Chest X-ray exposure doubled BC risk. A 3% increased BC risk per additional exposure was observed. Being 20 years old or younger at first exposure or being exposed before first full-term pregnancy did not seem to modify this risk. Birth after 1960 or carrying a rare likely deleterious coding variant in a DNA repair gene other than BRCA1/2 modified the effect of chest X-ray exposure.

CONCLUSION:

Ever/never chest X-ray exposure increases BC risk 2-fold regardless of age at first exposure and, by up to 5-fold when carrying 3 or more rare variants in a DNA repair gene. Further studies are needed to evaluate other DNA repair genes or variants to identify those which could modify radiation sensitivity. Identification of subpopulations that are more or less susceptible to ionizing radiation is important and potentially clinically relevant.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Radiografía / Predisposición Genética a la Enfermedad Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Radiografía / Predisposición Genética a la Enfermedad Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Francia